GB1507671A - Adamantane derivatives - Google Patents
Adamantane derivativesInfo
- Publication number
- GB1507671A GB1507671A GB952174A GB952174A GB1507671A GB 1507671 A GB1507671 A GB 1507671A GB 952174 A GB952174 A GB 952174A GB 952174 A GB952174 A GB 952174A GB 1507671 A GB1507671 A GB 1507671A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aminomethyl
- general formula
- halo
- prepared
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 title 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910000039 hydrogen halide Inorganic materials 0.000 abstract 1
- 239000012433 hydrogen halide Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
- C07D303/06—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms in which the oxirane rings are condensed with a carbocyclic ring system having three or more relevant rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1507671 2 - Halo - 1 - aminomethyl - adamantanes LILLY INDUSTRIES Ltd 4 April 1975 [2 March 1974 (2)] 9521/74 and 9576/74 Heading C2C Novel 2 - halo - 1 - aminomethyl - adamanwherein X is a halogen atom, R<SP>1</SP> is a hydrogen atom or C 1-4 alkyl gtoup and each of R<SP>2</SP> and R<SP>3</SP> is a hydrogen atom or C 1-4 alkyl group or NR<SP>2</SP>R<SP>3</SP> is a mononuclear heterocyclic ring having 4-6 carbon atoms and not more than 2 heteroatoms, the ring being optionally substituted by phenyl or C 1-4 alkyl, and acid addition salts thereof, are prepared by reacting a 4- aminomethyl-protoadamantane-4-ol of the general formula with HX and optionally N-alkylating a product in which at least one of R<SP>2</SP> and R<SP>3</SP> is a hydrogen atom, followed optionally by salification. 4 - Aminomethyl - protoadamantane - 4 - ols of the second general formula above and acid addition salts thereof are prepared by reacting an oxirane of the general formula with R<SP>2</SP>R<SP>3</SP>NH, followed optionally by salification. 1 - R<SP>1</SP>CH(OH) - 2 - R - adamantanes, wherein R is a halogen atom or hydroxy group, are prepared by treating an oxirane of the third general formula above with (a) when R is a halogen atom, a hydrogen halide under anhydrous conditions or (b) when R is a hydroxy group, an aqueous solution of an inorganic acid. Pharmaceutical compositions having anti- Parkinson activity comprise, as active ingredient, a 2-halo-1-aminomethyl-adamantane of the first general formula above or a pharmaceutically acceptable, non-toxic acid addition salt thereof, in association with a pharmaceutically acceptable carrier therefor.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB952174A GB1507671A (en) | 1974-03-02 | 1974-03-02 | Adamantane derivatives |
| US05/566,502 US4061774A (en) | 1974-03-02 | 1975-04-09 | Halogenated amino methyl adamantane derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB952174A GB1507671A (en) | 1974-03-02 | 1974-03-02 | Adamantane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1507671A true GB1507671A (en) | 1978-04-19 |
Family
ID=9873582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB952174A Expired GB1507671A (en) | 1974-03-02 | 1974-03-02 | Adamantane derivatives |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1507671A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2152924C1 (en) * | 1998-11-30 | 2000-07-20 | Волгоградский государственный технический университет | Method of preparing 1-(adamant-1-yl)ethylamine and homologues thereof |
-
1974
- 1974-03-02 GB GB952174A patent/GB1507671A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2152924C1 (en) * | 1998-11-30 | 2000-07-20 | Волгоградский государственный технический университет | Method of preparing 1-(adamant-1-yl)ethylamine and homologues thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1294763A (en) | 3-oxo-2,3-dihydro-1,4-benzoxazine derivatives | |
| GB1377231A (en) | Basically substituted benzyl-phthalazinone derivatives acid addition salts thereof and process for the production thereof | |
| GB1239029A (en) | ||
| GB1295228A (en) | ||
| GB1456627A (en) | Pyridobenzodiazepinones | |
| GB1212460A (en) | Naphthacene derivatives | |
| GB1452448A (en) | Derivatives of 2-amino-1,3-thiazine | |
| GB1456674A (en) | Neomycin derivatives | |
| GB1507671A (en) | Adamantane derivatives | |
| ES417006A1 (en) | 2-Amino-4-phenyl-2-imidazolines and salts thereof | |
| GB1383888A (en) | Amino ether derivatives of orthothymatic esters | |
| ES474367A1 (en) | New benzo [d] thiazole derivatives, process for their preparation and their therapeutic applications | |
| GB1355718A (en) | 2-amino-5-chloro-thiazole derivatives | |
| GB1449802A (en) | Piperazine derivatives and compositions containing them for treating parkinsons disease | |
| GB1296802A (en) | ||
| GB1053301A (en) | ||
| GB1429045A (en) | Hiazole cardiovascular agents | |
| GB1490771A (en) | 2-substituted 4,5-diphenylthiazoles and synthesis thereof | |
| GB1305725A (en) | ||
| GB1390320A (en) | Benzothiadiazines | |
| GB1428883A (en) | 1,3-benzoxazine and phenyl-alkylamine derivatives | |
| GB1456525A (en) | Process for the manufacture of alkanolamine derivatives | |
| GB1497149A (en) | Quaternary ammonium salts | |
| GB1418831A (en) | Reserpine derivatives | |
| GB1339010A (en) | Tetrazolyl-anthraquinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed |